DaVita HealthCare Partners Inc. (DVA) Short Interest Up 35.9% in August
DaVita HealthCare Partners Inc. (NYSE:DVA) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,638,958 shares, a growth of 35.9% from the August 15th total of 2,678,130 shares. Based on an average daily volume of 2,437,495 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.8% of the shares of the stock are sold short.
DaVita HealthCare Partners (NYSE:DVA) opened at 64.44 on Monday. The stock has a market cap of $13.33 billion, a PE ratio of 37.49 and a beta of 1.07. DaVita HealthCare Partners has a 1-year low of $61.36 and a 1-year high of $78.94. The stock has a 50 day moving average price of $68.99 and a 200-day moving average price of $73.34.
DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Monday, August 8th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.03. The company had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 earnings per share. On average, equities analysts expect that DaVita HealthCare Partners will post $3.76 EPS for the current year.
Several brokerages have recently commented on DVA. Wells Fargo & Co. reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research report on Saturday, June 4th. Zacks Investment Research upgraded DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research report on Tuesday, July 5th. JPMorgan Chase & Co. raised their price target on DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. Citigroup Inc. began coverage on DaVita HealthCare Partners in a research report on Tuesday, September 6th. They set a “neutral” rating and a $71.00 price target on the stock. Finally, Bank of America Corp. lowered DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 price target on the stock. in a research report on Tuesday, September 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $76.50.
In other news, insider Jeanine Marie Jiganti sold 4,620 shares of the stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $77.45, for a total transaction of $357,819.00. Following the transaction, the insider now directly owns 7,590 shares in the company, valued at approximately $587,845.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael David Staffieri sold 20,262 shares of the stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total value of $1,480,949.58. Following the transaction, the chief operating officer now owns 52,279 shares in the company, valued at $3,821,072.11. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.
Several large investors have recently bought and sold shares of DVA. Checchi Capital Advisers LLC increased its stake in DaVita HealthCare Partners by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 1,556 shares of the company’s stock worth $120,000 after buying an additional 37 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of DaVita HealthCare Partners during the second quarter valued at $147,000. Mizuho Asset Management Co. Ltd. boosted its stake in shares of DaVita HealthCare Partners by 78.7% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,191 shares of the company’s stock valued at $169,000 after buying an additional 965 shares during the last quarter. Feltz Wealth PLAN Inc. bought a new stake in shares of DaVita HealthCare Partners during the second quarter valued at $186,000. Finally, Global X Management Co. LLC boosted its stake in shares of DaVita HealthCare Partners by 59.2% in the second quarter. Global X Management Co. LLC now owns 2,422 shares of the company’s stock valued at $187,000 after buying an additional 901 shares during the last quarter. Institutional investors own 83.65% of the company’s stock.
About DaVita HealthCare Partners
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.